Clinical characteristics and exacerbation risk of chronic obstructive pulmonary disease patients with persistent type 2 inflammation on inhaled corticosteroid

Chan,M. C.,Law,A. K. P.,Yeung,Y. C.
DOI: https://doi.org/10.1183/13993003.congress-2024.pa4825
IF: 24.3
2024-11-01
European Respiratory Journal
Abstract:Background: The role of type 2 biomarker fractional exhaled nitric oxide (FeNO) in COPD remains controversial. While inhaled corticosteroid (ICS) can suppress FeNO, no studies have targeted patients with persistently elevated FeNO on ICS. Aims: To investigate the clinical characteristics and exacerbation risk of COPD patients on ICS with high FeNO. Methods: A retrospective study was conducted in COPD patients on ICS who had FeNO test from January 2016 to December 2023 in Princess Margaret Hospital. Patients with previous physician-diagnosed asthma were excluded. The clinical characteristics of high (≥20ppb) and low FeNO (<20ppb) patients were compared by Chi-square and T-test. Association between COPD exacerbations in the past 12 months and FeNO was assessed by logistic regression. Results: 107 COPD patients on ICS performed FeNO test during the study period. 41 (38%) of them had high FeNO and 66 (62%) had low FeNO. High FeNO group had significantly higher blood eosinophil (470 cells/μL vs. 230 cells/μL, p = 0.028) and more exacerbations in previous 12 months (2.1 vs. 0.7, p = 0.007). On simple logistic regression, high FeNO and post-bronchodilator FEV1 had significant association with exacerbation, with OR 2.26 (p = 0.045) and 0.98 (p = 0.031) respectively. Adjusted OR for high FeNO was 2.48 (p = 0.037) on multiple logistic regression. Combining high FeNO and blood eosinophil further increased adjusted OR to 4.02 (p=0.022). Conclusion: COPD patients on ICS with elevated FeNO, especially with high blood eosinophil, had increased risk of exacerbations. Prospective study is required to further investigate the association.
respiratory system
What problem does this paper attempt to address?